Keyphrases
Neoadjuvant Chemotherapy
100%
Tremelimumab
100%
Before Surgery
100%
HER2-positive
100%
Breast Cancer
100%
PD-1 Blockade
100%
Durvalumab
100%
KDM6B
100%
Immune-related Myositis
100%
Hormone Receptor-positive
100%
Glioblastoma
100%
Myeloid Cells
57%
Breast Reconstruction
50%
Combination Immunotherapy
50%
HER2-negative Breast Cancer
50%
Functional Phenotype
42%
Glioblastoma multiforme
42%
Immune Checkpoint Therapy
42%
Immune-suppressive
42%
Immunosuppressive Myeloid Cells
42%
Cell Subsets
28%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
25%
Checkpoint Blockade
25%
Disease Progression
25%
Colitis
25%
Stable Disease
25%
Endocrinopathy
25%
Tumor Microenvironment
25%
2-cycles
25%
Programmed Death-ligand 1 (PD-L1)
25%
Immune Parameters
25%
Clinical Trials
25%
Breast Ultrasound
25%
Pathological Complete Response
25%
Tumor Volume
25%
Immunotherapy Toxicity
25%
Immune-related Adverse Events
25%
Checkpoint Inhibition
25%
Interferon Response
14%
Pharmacological Inhibitors
14%
Mechanistic Studies
14%
Putative Drug Targets
14%
Immune Suppression
14%
Tumor-bearing Mice
14%
Lysine
14%
Single-cell Transcriptome Analysis
14%
Epigenetics
14%
Epigenetic Regulators
14%
Improved Survival
14%
Enhanced Response
14%
Medicine and Dentistry
Breast Cancer
100%
Neoadjuvant Chemotherapy
100%
Hormone Receptor
100%
Myeloid Cell
100%
Durvalumab
100%
Glioblastoma
100%
Ticilimumab
100%
Immunity
85%
Immunotherapy
75%
Neoplasm
67%
Breast Surgery
50%
Immunocompetent Cell
25%
Colitis
25%
Clinical Trial
25%
Endocrine Disease
25%
Breast Ultrasound
25%
Programmed Death-Ligand 1
25%
Tumor Microenvironment
25%
Disease Exacerbation
25%
CTLA-4
25%
Immune-Related Adverse Events
25%
Diseases
25%
Mediator
14%
Immunosuppressive Treatment
14%
Antigen Presentation
14%
Interferon
14%
Lysine
14%
Phagocytosis
14%
Gene Expression Profiling
14%